Gestione del paziente nel pre e post trapianto di fegato
|
|
- Silvia Garrison
- 6 years ago
- Views:
Transcription
1 Gestione del paziente nel pre e post trapianto di fegato Maria Rosaria Piras SSD SSD Coordinamento Trapianto di Fegato Azienda Ospedaliera Brotzu Cagliari
2 HCV Infection and Liver Transplantation HCV infection is the 1 cause of liver transplantation in industrialized countries BUT Universal reinfection after LT Negative impact on long-term survival Up to 1/3 of HCV transplanted patients will develop an accelerated course to cirrhosis within 5 yrs following LT Recurrence prevention Berenguer M et al Hepatology 2000;32: Neumann UP et al Transplantation 2004: 77: , Belli L et al Liver Transpl 2007;13: , Burra P et al J Hepatol 2013
3 Treatment Pre-LT with the Goal of Preventing HCV Recurrence Antiviral Antiviral Therapy Therapy for wks Strategy 1: Treat to Cure SVR LT 100% HCV-free post- LT No SVR 100% HCV- infected post-lt Strategy 2: Treat to Achieve HCV RNA Undectability Antiviral Therapy until HCV RNA negative for 4 wks LT Follow up On-Treatment Response 95% HCV-free post-lt if HCV RNA negative at LT Adapted from Terrault N EASL 2015
4 Treatment Pre-LT with the Goal of Preventing HCV Recurrence Antiviral Antiviral Therapy Therapy for wks Strategy 1: Treat to Cure SVR LT 100% HCV-free post- LT No SVR Shorter duration 100% HCV- infected post-lt of therapy Strategy 2: Treat to Achieve HCV RNA Undectability Antiviral Therapy until High HCV % of RNA patients negative achieve for TND 4 wks HCV RNA on DAAs On-Treatment Response LT Follow up 95% HCV-free post-lt if HCV RNA negative at LT Adapted from Terrault N EASL 2015
5 Solar-1: LDV/SOF + RBV in decompensated cirrhosis Results: SVR 12 N=108 HCV GT 1a 76% IL 28B non CC 72% TE 65% Flamm, AASLD, 2014, Oral #239
6 LABORATORY RESULTS: MELD SCORE CHANGE FROM BASELINE TO FOLLOW-UP WEEK 4 Laboratory results: MELD score change from baseline to follow up week 4 CPT B CPT C 12 wk (n=30)* 24 wk (n=29)* 12 wk (n=23)* 24 wk (n=26)* (+10) 36% not improved 35% not improved n=5 n=5 n=2 n=3 *Missing FU-4: n=2 CPT B 12 wk; n=4 CPT B 24 wk; n=2 CPT C 12 wk; n=7 CPT C 24 wk. Flamm, AASLD, 2014, Oral #239
7 Advanced cirrhosis N=60 Post-LT N=53 DCV 60 mg QD SOF 400 mg QD+RBV Follow-up Week 0 Week 12 Week 24 Week 36 SVR 12 HCV GT 1-75% (GT1a 57%) IL28B non CC 78% Naive or experienced patients DAA failures allowed except NS5A HCC allowed CTP B-C 80% Advanced cirrhosis patients with treatment interrupted by LT could receive an additional 12 wks of treatment immediately post-lt
8 SVR 12 by HCV Genotype and CTP Class: Ally-1 Study Advanced cirrhosis cohort N=60 Patients with relapse: DCV + SOF + RBV 24 wks Ch Child-Pugh Class
9 Cirrhotic Patients Transplanted During Treatment: Ally-1 Study *Discontinued RBV after 11 days due to hyperbilirubinemia resulting from post-lt biliary obstruction
10 Post-Transplant HCV Recurrence in patients in whom HCV RNA was non detectable for 28 days prior to transplant No Recurrence (n=29) Recurrence (n=10) Cirrhosis + HCC CTP 7 MELD exception for HCC 48 wks or LT No AEs due to SOF/RBV No recurrence in 24/25 (96%) of patients who maintained HCV RNA TND >28 days 28. Curry MP et al, Gastroenterology 2015
11 EASL 2015 Guidelines Antiviral Therapy on the Waiting List in Decompensated Cirrhosis Pawlotsky JM EASL 2015
12 Antiviral therapy on the waiting list Objective: Improve liver function About 1/3 of CTP B or C patients not improved despite HCV suppression Predictors of potential de-listing still unknown About 2/3 of patients could be transplanted with lower MELD score Objective: prevent HCV recurrence Clear predictors of success Not always easy to apply Date of LT unpredictable Suitable for low MELD score Ideal for LDLT No impact on waiting list Openned questions Is 4 wks negativity the best prediction rule? Can adjuvant therapies e.g. HCIG improve SVR rates post-lt? Should DAA be continued post-lt for a limited time?
13 Strategies to use antiviral therapy in the context of LT STRATEGIES TO USE ANTIVIRAL THERAPY IN THE CONTEXT in HCV positive recipients OF LIVER TRANSPLANTATION IN HCV POSITIVE RECIPIENTS Listing Transplant Follow-up Target population FCH RF BC F2 F0-F2 Antiviral therapy Cure the HCV recurrence FCH: fibrosing cholestatic hepatitis RF: rapid fibrosers BC: biliary complicathions
14 SVR rates with triple therapy in Liver Transplant patients P IFN+R BV 30% 52% n = 273 n = 54 n = 95 n = 54 Death Infections Anemia Renal failure Rejection DDI Rehospitalization 27/35 BOC TVR Wang CS et al Am J Transpl 2006;6: , Hirouchakis et al J Viral Hepat 2008;15: Wierner, Coilly, Puanpong, Stravitz, Nair 2013
15 Treatment after Liver Transplantation SOF + RBV 24 weeks Author N Genotype 1 Cirrhosis Time after LT Charlton M 40 83% 40% 4,3 yr Forns X % 50% (50% FCH) 17 mo Samuel D 40 83% 40% 4.3 yr Initial RBV dose 400 mg/d Charlton M et al, Gastroenterology 2015, Forns X et al Gastroenterology 2015, Samuel D et al EASL 2014
16 Results: Post-Transplant Virologic Response SOF + RBV 24 weeks 70% 70% NO DDI No rejection 59% Charlton Forns Samuel SVR 12 SVR 12 SVR 12 Charlton M et al, Gastroenterology 2015, Forns X et al Gastroenterology 2015, Samuel D et al EASL 2014C
17 Treatment after Liver Transplantation SOF Simeprevir RBV + ± weeks Author N GT 1 Cirrhosis RBV SVR Brown R % 60% 22% 91% Pupapon S % 29% 22% 91% Te H % 35% (F3- F4) 0% 71% Treatment safe and well tolerated 1-2 AASLD 2014, 3 EASL 2015
18 N=19 GT1a N=9 F4 53% 3 mos after LT TE 84% (21% + PI) 12 wks Safe & well tolerated 100% 90% 80% 70 60% 50% 40% 30% 20% 10% 0% F3 GT1a F4 F3 GT1b F4 SVR 12
19 Treatment after LT: ALLY-1 Study SOF Daclatasvir RBV + + Advanced cirrhosis N=60 Post-LT N=53 DCV 60 mg QD SOF 400 mg QD+RBV Follow-up Post-LT HCV GT1-77% (GTa 58%) IL 28B non CC 75% Naive or experienced patients F3/F4-55% 3 mo. after LT Any immunosuppressive regimen Week 0 Week 12 Week 24 Week 36 SVR 12 Poodard F et al EASL 2015
20 SVR12 by HCV Genotype and by cohort: ALLY-1 Study Patients with relapse: DCV + SOF + RBV 24 wks No DDI No graft rejection Well tolerated Poodard F et al EASL 2015
21 Treatment after LT: CUPILT Study SOF Daclatasvir RBV + ± N=130 Most F3-F4 FCH 10% Most patients 24 wks Most patients without RBV Safe and well tolerated Attention to renal failure Coilly et al, EASL 2015
22 Virological Resonse According to Treatment Duration CUPILT Study SOF + Daclatasvir ± RBV EOT SVR % 100% 100% 97% 98% 96% 67% 67% Virologic Breakthrough n=1 Lost of FU n=1 Relapse n=1 Death n=2 wk1 & FU wk6 SOF+DCV (n=11) Coilly et al, EASL 2015 SOF+DCV+RBV (n=3) SOF+DCV (n=64) Week 12 Week 24 SOF+DCV+RBV (n=52)
23 Treatment after LT: Solar-1 Study SOF Ledipasvir RBV + + Wk 0 Wk 12 Wk 24 Wk 36 N=112 LDV/SOF + RBV N= 223 GT1,4 TN & TE 3 mo. from LT F0-F3 N=111 CTP A (n=51),b (n=52),c (n=9) CTP B,C RBV dose escalation N=111 LDV/SOF + RBV SVR 12 were similar with 12 or 24 wks of treatment SVR12 SVR12 Reddy, AASLD 2014, #8 8 CTP B 24 wk & CTP C 24 wk patients have not reached the wk 12 post-treatment visit Error bars represent 2-sided 90% exact confidence intervals
24 GT1a N=392 GT1b N=224 GT4 N= 42 N=658 Conclusions In these patient populations treatment with LDV/SOF + RBV was generally safe and well tolerated, irrespective of the degree of decompensation or whether patients were pre- or-post transplantation
25 12-24 wks N=12 Males 75% Caucasian 85% GT1a 75% TE 75% N=9 completed treatment N=3 on treatment No treatment discontinuation 5 SAEs (1TR dyspnea) On-treatment wk 4 Follow up wk 4 N=11/12 HCV RNA < LLOQ N=8/8 SVR
26 Treatment after LT: SATURN Study Daclatasvir Simeprevir RBV + + N=35 GT 1b Mild fibrosis N=21 F1-F4 N=14 TN & TE 24 week treatment CNI interaction (CsA/SMV) Treatment safe and well tolerated Forns et al, EASL 2015 F1-F2 F1-F4 Follow-up week 4
27 Treatment after LT Paritaprevir/R Ombitasvir Daclatasvir RBV N=34 All GT1 F2= 2 TN & TE CNIs adjustement for ABT450/RTV Mild AEs 5 patients recived EPO Kwo et al, NEJM 2014
28 EASL 2015 Guidelines Post-LT Recurrence DDI interactions
29 1-Conclusions Treatment of HCV infection in patients awaiting LT is a good strategy to prevent HCV graft infection: it will increase survival an simplify post-lt follow-up Viral clearance may be associated with improvement in liver function, leading to delisting in some cases Treatment is not recommended in patients with very advanced liver disease All patients with HCV infection after LT are candidates for IFN-free antiviral therapy Treatment is recommended at an early stage of hepatitis C recurrence, preferably when patients are in stable condition (immunosuppression, renal function.) In those cases of early recurrence (cholestatic forms) treatment shoud be administered as soon as the diagnosis is made
30 2-Conclusions Expected huge impact on patient and graft survival, selection of candidates for LT considered at great risk of severe HCV recurrence (females with high MELD score, HIV coinfected) Expected reduced impact of donor age and D/R match, suboptimal donors (steatosis,ischemia time, DCD) HCV positive donors
31 Complicanze pre e post Trapianto di fegato fpost-olt NAFLD Insufficienza renale acuta più frequente nel post operatorio Patogenesi multifatoriale e fattori in parte comuni a iperlipemia e diabete Stile di vita, modifiche immunosoppressione Osteopenia e fratture spontanee frequenti soprattutto I semestre Grazie post-olt per l attenzione Patogenesi m. colestatica, deficit e sintesi ed assorbimento vit.d, Malnutrizione, ipogonadismo, immobilità, diuretici, Cise rapida perdita massa, recente Osteopenia e fratture spontanee frequenti semestre post-olt Patogenesi multiffatoriale: m. colestatiche, deficit sintesi e metabolismo vit.d deficit assorbimanto calcio, malnutrizione, ipoginadismo, allettamento, diuretici rapida perdita massa ossea primo periodo post-olt, terapia immunosoppressiva, IRC jatrogena Calcio, vit. D e bifosfonati evidenza utilità Orlistat
32 EASL 2015 Guidelines Antiviral therapy is indicated in patients awaiting liver transplantation because it prevents graft infection Treatment should be initiated as soon as possible to complete a full treatment course before transplantation The optimal timing (i.e. before transplantation or post-transplantation) to maximize survival is still debatable and require individual assessment
33 Antiviral Therapy post-lt: Key Points Antiviral therapy after LT to cure HCV recurrence - The real extraordinary innovation - Effective and safe in all non cirrhotic recipients - Absent or easy manegeable DDI Expected huge impact on: - Patient and graft survival - Selection of candidates for LT considered at great risk of severe HCV recurrence ( females with high MELD score, HIV coinfected) Expected reduced impact of: - Donor age and D/R match - Suboptimal donors (steatosis,ischemia time, DCD) - HCV positive donors
34 Openned Questions Treat before or after LT? If before LT, when? (MELD?) Remove patients from the waiting list? Best combination for each patient? Duration of treatment? RBV yes or no? How to avoid relapse? Risk of liver failure? More data is needed concerning safety
35 Conclusions The number of liver tansplants due to HCV related cirrhosis will be influenced by the efficacy and the widespread applicability of antiviral therapies to prevent/reduce liver decompensation and HCC occurence The success of liver transplants in HCV related cirrhosis will be influenced by the efficacy an widespread applicability of antiviral therapies to prevent/cure HCV recurrence
36 Treatment Pre-LT with the Goal of Preventing HCV Recurrence Antiviral Antiviral Therapy Therapy for for wks Strategy 1: Treat to Cure SVR LT 100% HCV-free post- LT No SVR 100% HCV- infected post-lt Strategy 2: Treat to Achieve HCV RNA Undectability Antiviral Therapy until HCV RNA negative for 4 wks LT Follow up On-Treatment On-Treatment Response Response Terrault N EASL 2015 with permission 95% HCV-free post-lt if HCV RNA negative at LT
37 Treatment after Liver Transplantation SOF Simeprevir RBV + ± weeks Author N GT 1 Cirrhosis RBV SVR Brown R % 60% 22% 91% Pupapon S % GT1a 62% Te H % GT1a 62% 29% 22% 91% 35% (F3- F4) 0% 71% 1-2 AASLD 2014, 3 EASL 2015
38 Antiviral Therapy in Transplant Setting EASL 2015 Guidelines SOF + RBV GT 2 SOF/SIM* + RBV GT 1-4 SOF/LDV + RBV GT SOF/DCV/ + RBV All 3D# ± RBV GT 1 *Not recommended for decompensated cirrhosis #Paritaprevir-r/Ombitasvir/Daclatasvir not recommended for decompensated cirrhosis
39 Real world experience in the HCV-Target cohort: An International Consortium
40 Safety and Efficacy of Post-Transplant Patients Treated with SOF-Containing Regimens for HCV HCV-Target -Post Transplant Brown AASLD 2014#LB-4
41 Safety and Efficacy of Post-Transplant Patients Treated with SOF-Containing Regimens for HCV HCV-Target -Post Transplant Brown AASLD 2014#LB-4
42 SVR 4+ (%) Safety and Efficacy of new DAA-based therapy for HCV posttransplant -SVR 4 + in GT1 with SMV +SOF ±RBV HCV-Target -Post Transplant 61 /68 9 /11 52 /57 32 /37 29 /31 33 /37 26 /31 11 /12 10 /13 30 /36 18 /19 Yes No Yes No < a 1b Brown AASLD 2014#LB-4
43
44
45
46 EASL Recommendations on Treatment of Hepatitis C 2015 Journal of Hepatology DOI: /j.jhep Copyright 2015 European Association for the Study of the Liver Terms and Conditions
47
48
49
50
51 Mean egfr change (ml/min) Patients (%) Mean creatinine change (mg/dl) DDI interactions (SOF) and renal parameters (SOF/LDV) in transplanted patients ERADICATE select KT Study mean (NIAID, CR CHANGES SOFL/DV) Sofosbuvir Creatinine ARV Untreated ARV Treated TAC MMF P CyA Aza TAC tacrolimus, MMF mycophenolate mofetil, P prednisone CyA cyclosporin AZA azathioprin No interactions reported between SOF and any immunosuppressive agents Charlton MR EASL Day 0 Wk 2 Wk 4 Wk 8 Wk 12 SVR 2 SELECT GFR NARV vs ARV SVR 12 Estimated Glomerular Filtration Rate ARV Untreated ARV Treated -30 Day 0 Wk 2 Wk 4 Wk 8 Osinusi A, EASL 2014 Wk 12 SVR 2 SVR 12
52 LDV/SOF + RBV for Treatment of HCV in Patients with Post-Transplant Recurrence SOLAR-1 Wk 0 Wk 12 Wk 24 Wk 36 N=112 LDV/SOF + RBV SVR12 N=111 LDV/SOF + RBV SVR12 N= 223 GT1,4 TN & TE 3 mo. from LT F0-F3 N=111 CTP A (n=52),b (n=52),c (n=9) CTP B,C RBV dose escalation Reddy, AASLD 2014, #8 8 CTP B24 wk & CTP C 24 wk patients have not reached the wk 12 post-treatment visit Error bars represent 2-sided 90% exact confidence intervals
53 Treatment Pre-LT with the Goal of Preventing HCV Recurrence Strategy 1: Treat to Cure Antiviral Therapy for wks SVR LT 100% HCV-free post- LT No SVR 100% HCV- infected post-lt Strategy 2: Treat to Achieve HCV RNA Undectability Antiviral Therapy until HCV RNA negative for 4 wks LT Follow-up On-Treatment Response 95% HCV-free post-lt if HCV RNA negative ay LT Adapted from Terrault N EASL 2015
54 Advanced cirrhosis cohort: SVR 12 by HCV GT and CTP Ally Ally-1 Study N=60 Patients with relapse: DCV+ + SOF + RBV 24 wks
55 MELD Scores Baseline to Posttreatment week 12
Treatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Treatment of Hepatitis C Recurrence after Liver Transplantation Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Agenda 1. Introduction 2. Treatment options for hepatitis C recurrence after transplantation
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationTreating HCV After Liver Transplantation: What are the Treatment Options?
4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationDAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France
DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment
More informationHCV Therapy in Liver Transplant Candidate
PHC 216 HCV Therapy in Liver Professor Didier SAMUEL Transplant Candidate Dr Audrey COILLY Centre Hépato-Biliaire, Inserm 1193 Treat before orrearch afuniter? University Paris Sud A Villejuif u d r e yfrance
More informationTreatment of recurent hepatitis infection after liver transplantation
Paris PHC, 11 janvier 2016 Treatment of recurent hepatitis infection after liver transplantation Georges-Philippe Pageaux CHU Saint Eloi, Digestive department gp-pageaux@chu-montpellier.fr Disclosures
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationHepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of
Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationSOLAR-1 (Cohorts A and B)
Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; 149:649-59. Ledipasvir-Sofosbuvir
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationHCV TREATMENT PRE- AND POST TRANSPLANTATION
HCV TREATMENT PRE- AND POST TRANSPLANTATION Mitchell L. Shiffman, MD, FACG Medical Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA IVer Liver Institute
More informationHCV Treatment in 2016
HCV Treatment in 2016 Hugo E. Vargas, MD Professor of Medicine Mayo College of Medicine Medical Director, Clinical Trials Office Vice Chair, Department of Research Educational Goals Caveats: Cannot cover
More informationDAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo
DAAs in the era of decompensated liver disease Piero L. Almasio University of Palermo piero.almasio@unipa.it HCV therapy in the era of interferon based therapy Priority Compensated cirrhosis Decompensated
More informationSOLAR-1 (Cohorts A and B)
Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; [Epub ahead of print]
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationLiver transplantation and hepatitis C virus
Liver transplantation and hepatitis C virus Where do we come from? Where are we? Where are we going? François Durand Hépatologie & Réanimation Hépato-Digestive INSERM U1149 Hôpital Beaujon, Clichy HCV:
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationTransplantation. Professor Didier. Centre Hépatobiliaire, Hépatobiliaire, C.H.B.
Treatment Treatment of of Hepatitis Hepatitis C C in in Liver Liver Transplantation Transplantation Professor Professor Didier Didier Samuel Samuel Centre Centre Hépatobiliaire, Hépatobiliaire, Inserm
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More informationPatients with Cirrhosis: Managing the HCV Peri-Transplant Patient
Patients with Cirrhosis: Managing the HCV Peri-Transplant Patient Fred Poordad, MD Professor of Medicine University of Texas Health Science Center VP, Academic and Clinical Affairs The Texas Liver Institute
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationDirect-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients
Editorial Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients Nobuhisa Akamatsu, Junichi Togashi, Kiyoshi Hasegawa, Norihiro Kokudo Artificial Organ and Transplantation
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationThe future of liver transplantation for viral hepatitis
The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:
More informationAddressing Unmet Medical Needs in HCV Genotype 3
Addressing Unmet Medical Needs in HCV Genotype 3 Karen Doucette, MD, MSc (Epi), FRCPC Associate Professor, Division of Infectious Diseases, Department of Medicine University of Alberta Objectives Identify
More informationNext generation DAAs: Combining efficacy and safety profile. Jiannis Vlachogiannakos
Next generation DAAs: Combining efficacy and safety profile. Jiannis Vlachogiannakos Associate Professor of Gastroenterology, Academic Department of Gastroenterology, National and Kapodistrian University
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationManagement of HCV in Decompensated Liver Disease
Management of HCV in Decompensated Liver Disease Michael P. Manns Hannover Medical School (MHH) Department of Gastroenterology, Hepatology and Endocrinology Helmholtz Center for Infection Research (HZI),
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationMulticenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment
ORIGINAL ARTICLE September-October, Vol. 17 No. 5, 2018: 815-821 815 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationRecurrent HCV after a Pre-LTx Course of SOF/DAC:
Recurrent HCV after a Pre-LTx Course of SOF/DAC: Didier Samuel, Teresa Antonini Centre Hépato-Biliaire, Inserm Paris Sud Research Unit 1193 Hôpital Paul Brousse, Villejuif, France 3 rd Optimize Workshop,
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More informationDuncan Webster, BSc, BA, MA, MD, FRCPC
Moderator Duncan Webster, BSc, BA, MA, MD, FRCPC Internist, Infectious Disease Physician, Department of Medicine Medical Microbiologist, Department of Laboratory Medicine, Saint John Regional Hospital
More informationHCV: Current SOTA of Management of Treatment Experienced Patients
HCV: Current SOTA of Management of Treatment Experienced Patients Robert G Gish MD Professor Consultant Stanford University Executive Committee: National Viral Hepatitis Roundtable Founding Member: CEVHAP
More informationTerapie attuali. Eradicazione di HCV e nuove prospettive:
Eradicazione di HCV e nuove prospettive: Terapie attuali Luisa Pasulo U.S.C. Gastroenterologia Epatologia e Trapiantologia Ospedale Papa Giovanni XXIII - Bergamo From Infection to liver disease Infezione
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationSummary from AASLD 2014 for Hepatitis C Boston 7-11 November 2014
Summary from AASLD 2014 for Hepatitis C Boston 7-11 November 2014 Feedback from the real-world: do HCV cure rates in real-life patient cohorts hold what clinical trials promised? Summary from AASLD 2014
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationIs Treatment cost effective HCV and Organ Transplantation
Is Treatment cost effective HCV and Organ Transplantation Dr Kosh Agarwal Institute of Liver Studies King s College Hospital Barcelona 2016 Disclosures: BoJo Pharma support: AbbVie/Achillion/ Astellas/
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationVIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
More informationTreatment of Patients with HCV and HIV
Treatment of Patients with HCV and HIV BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Four Questions Is HIV/HCV
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationHepatitis C Difficult to Treat. Population. Disclosures
Hepatitis C Difficult to Treat Populations Paul Y Kwo MD Professor of Medicine Director of Hepatology Stanford University School of Medicine 75 Welch Road #21 Palo Alto, CA 9434 Disclosures Advisory Board
More informationI nuovi farmaci per HCV: frequenza della patologia, evidenze di efficacia e sicurezza, strategie di gestione. la pratica clinica
I nuovi farmaci per HCV: frequenza della patologia, evidenze di efficacia e sicurezza, strategie di gestione La revisione ii delle dll evidenze e indicazioni i iper la pratica clinica Marco Marzioni Segretario
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationHIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER LONDON
HIV/Hepatitis C in France: data from real life cohorts LIONEL PIROTH CHU DIJON UNIVERSITY OF BURGUNDY DECEMBER 2015 - LONDON The need Decreasing prevalence of chronic hepatitis C in French people living
More informationHepatitis B and Hepatitis C Virus in non-liver Transplant Recipients. Karim Qumosani MD, FRCPC, ABIM, MdMEd Multi-organ Transplant Unit, London
Hepatitis B and Hepatitis C Virus in non-liver Transplant Recipients Karim Qumosani MD, FRCPC, ABIM, MdMEd Multi-organ Transplant Unit, London Financial Disclosures Research Grants Merck, Gilead, Abbvie,
More informationCase 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks
Treatment of HCV: Pre- vs Post- Transplant Roy D. Bloom MD Professor of Medicine University of Pennsylvania Roy D. Bloom MD Professor of Medicine Medical Director, Kidney Transplant Program University
More informationMy HCV patient is co-infected with HIV: how to manage?
EASL «White Nights of Hepatology 2016» My HCV patient is co-infected with HIV: how to manage? A.V. Кravchenko MD, Professor Russia AIDS Federal Center Central Research Institute of Epidemiology St.-Petersburg,
More information